Research programme: small molecule therapeutics - C4X Discovery
Latest Information Update: 28 Oct 2020
At a glance
- Originator C4X Discovery
- Class Anti-inflammatories; Antihyperglycaemics; Neuroprotectants; Small molecules
- Mechanism of Action G protein-coupled receptor agonists; Genome modulators; Glucagon-like peptide-1 receptor agonists; Interleukin 17 receptor antagonists; KEAP1 protein modulators; NF-E2-related factor 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Chronic obstructive pulmonary disease; Inflammation; Neurodegenerative disorders; Type 2 diabetes mellitus
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Cancer in United Kingdom
- 28 Sep 2020 No recent reports of development identified for research development in Autoimmune-disorders in United Kingdom (PO)
- 28 Sep 2020 No recent reports of development identified for research development in Inflammation in United Kingdom (PO)